Treatment of streptozotocin-induced diabetic rats with alogliptin: Effect on vascular and neural complications

Experimental Diabetes Research

Volumn 2011, Issue , 2011, Pages

  Davidson, Eric P ^a   Coppey, Lawrence J ^a   Dake, Brian ^a   Yorek, Mark A ^a,b  

^a UNIVERSITY OF IOWA   (United States)

^b VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLCHOLINE; ALOGLIPTIN; CALCITONIN GENE RELATED PEPTIDE; DIPEPTIDYL PEPTIDASE IV; INSULIN; STREPTOZOCIN; ANTIDIABETIC AGENT; DIPEPTIDYL PEPTIDASE IV INHIBITOR; DRUG DERIVATIVE; PIPERIDINE DERIVATIVE; URACIL;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; DRUG EFFECT; HYPOALGESIA; INSULIN DEPENDENT DIABETES MELLITUS; MALE; MOTOR NERVE CONDUCTION; NERVE FIBER; NONHUMAN; PRIORITY JOURNAL; RAT; SENSORY NERVE CONDUCTION; STREPTOZOCIN DIABETES; ANIMAL; BLOOD; DIABETIC ANGIOPATHY; DIABETIC NEUROPATHY; EXPERIMENTAL DIABETES MELLITUS; GLUCOSE BLOOD LEVEL; METABOLISM; MOTONEURON; NERVE CONDUCTION; OXIDATIVE STRESS; PAIN ASSESSMENT; PAIN THRESHOLD; PATHOPHYSIOLOGY; SENSORY RECEPTOR; SPRAGUE DAWLEY RAT; TIME; VASODILATATION; WEIGHT GAIN;

ANIMALS; BLOOD GLUCOSE; DIABETES MELLITUS, EXPERIMENTAL; DIABETES MELLITUS, TYPE 1; DIABETIC ANGIOPATHIES; DIABETIC NEUROPATHIES; DIPEPTIDYL-PEPTIDASE IV INHIBITORS; HYPOGLYCEMIC AGENTS; MALE; MOTOR NEURONS; NEURAL CONDUCTION; OXIDATIVE STRESS; PAIN MEASUREMENT; PAIN THRESHOLD; PIPERIDINES; RATS; RATS, SPRAGUE-DAWLEY; SENSORY RECEPTOR CELLS; TIME FACTORS; URACIL; VASODILATION; WEIGHT GAIN;

EID: 80052719404     PISSN: 16875214     EISSN: 16875303     Source Type: Journal    
DOI: 10.1155/2011/810469     Document Type: Article

References (40)

1. Coppey L. J., Davidson E. P., Dunlap J. A., Lund D. D., Yorek M. A., Slowing of motor nerve conduction velocity in streptozotocin-induced diabetic rats is preceded by impaired vasodilation in arterioles that overlie the sciatic nerve Experimental Diabesity Research 2000 1 2 131 143
2. Coppey L. J., Gellett J. S., Davidson E. P., Dunlap J. A., Yorek M. A., Effect of treating streptozotocin-induced diabetic rats with sorbinil, myo-inositol or aminoguanidine on endoneurial blood flow, motor nerve conduction velocity and vascular function of epineurial arterioles of the sciatis nerve International Journal of Experimental Diabetes Research 2002 3 1 21 36 (Pubitemid 35174542)
3. Davidson J. A., Incorporating incretin-based therapies into clinical practice: differences between glucagon-like peptide 1 receptor agonists and dipeptidyl peptidase 4 inhibitors Mayo Clinic Proceedings 2010 85 12 S27 S37
4. Lee B., Shi L., Kassel D. B., Asakawa T., Takeuchi K., Christopher R. J., Pharmacokinetic, pharmacodynamic, and efficacy profiles of alogliptin, a novel inhibitor of dipeptidyl peptidase-4, in rats, dogs, and monkeys European Journal of Pharmacology 2008 589 13 306 314
5. Neumiller J. J., Wood L., Campbell R. K., Dipeptidyl peptidase-4 inhibitors for the treatment of type 2 diabetes mellitus Pharmacotherapy 2010 30 5 463 484
6. Lam S., Saad M., Saxagliptin: a new dipeptidyl peptidase-4 inhibitor for type 2 diabetes Cardiology in Review 2010 18 4 213 217
7. Matteucci E., Giampietro O., Dipeptidyl peptidase-4 (CD26): knowing the function before inhibiting the enzyme Current Medicinal Chemistry 2009 16 23 2943 2951
8. Deacon C. F., Toft-Nielsen M., Pridal L., Willms B., Holst J. J., Both subcutaneously and intravenously administered glucagon-like peptide I are rapidly degraded from the NH2-terminus in type II diabetic patients and in healthy subjects Diabetes 1995 44 9 1126 1131
9. Kieffer T. J., McIntosh C. H. S., Pederson R. A., Degradation of glucose-dependent insulinotropic polypeptide and truncated glucagon-like peptide 1 in vitro and in vivo by dipeptidyl peptidase IV Endocrinology 1995 136 8 3585 3596
10. Mu J., Petrov A., Eiermann G. J., Woods J., Zhou Y. P., Li Z., Zycband E., Feng Y., Zhu L., Roy R. S., Howard A. D., Li C., Thornberry N. A., Zhang B. B., Inhibition of DPP-4 with sitagliptin improves glycemic control and restores islet cell mass and function in a rodent model of type 2 diabetes European Journal of Pharmacology 2009 623 13 148 154
11. Ferreira L., Teixeira-De-Lemos E., Pinto F., Parada B., Mega C., Vala H., Pinto R., Garrido P., Sereno J., Fernandes R., Santos P., Velada I., Melo A., Nunes S., Teixeira F., Effects of sitagliptin treatment on dysmetabolism, inflammation, and oxidative stress in an animal model of type 2 diabetes (ZDF rat) Mediators of Inflammation 2010 2010 11
12. Oltman C. L., Davidson E. P., Coppey L. J., Kleinschmidt T. L., Lund D. D., Yorek M. A., Attenuation of vascular/neural dysfunction in zucker rats treated with enalapril or rosuvastatin Obesity 2008 16 1 82 89 (Pubitemid 351271954)
13. Oltman C. L., Coppey L. J., Gellett J. S., Davidson E. P., Lund D. D., Yorek M. A., Progression of vascular and neural dysfunction in sciatic nerves of Zucker diabetic fatty and Zucker rats American Journal of Physiology 2005 289 1 E113 E122 (Pubitemid 40874942)
14. Obrosova I. G., Li F., Abatan O. I., Forsell M. A., Komjti K., Pacher P., Szab C., Stevens M. J., Role of poly(ADP-ribose) polymerase activation in diabetic neuropathy Diabetes 2004 53 3 711 720 (Pubitemid 38270641)
15. Beiswenger K. K., Calcutt N. A., Mizisin A. P., Epidermal nerve fiber quantification in the assessment of diabetic neuropathy Acta Histochemica 2008 110 5 351 362
16. Davidson E. P., Coppey L. J., Calcutt N. A., Oltman C. L., Yorek M. A., Diet-induced obesity in Sprague-Dawley rats causes microvascular and neural dysfunction Diabetes/Metabolism Research and Reviews 2010 26 4 306 318
17. Coppey L. J., Gellett J. S., Davidson E. P., Dunlap J. A., Lund D. D., Yorek M. A., Effect of antioxidant treatment of streptozotocin-induced diabetic rats on endoneurial blood flow, motor nerve conduction velocity, and vascular reactivity of epineurial arterioles of the sciatic nerve Diabetes 2001 50 8 1927 1937 (Pubitemid 33641615)
18. Coppey L. J., Davidson E. P., Rinehart T. W., Gellett J. S., Oltman C. L., Lund D. D., Yorek M. A., ACE inhibitor or angiotensin II receptor antagonist attenuates diabetic neuropathy in streptozotocin-induced diabetic rats Diabetes 2006 55 2 341 348 (Pubitemid 43343262)
19. Yorek M. A., Coppey L. J., Gellett J. S., Davidson E. P., Sensory nerve innervation of epineurial arterioles of the sciatic nerve containing calcitonin gene-related peptide: effect of streptozotocin-induced diabetes Experimental Diabesity Research 2004 5 3 187 193 (Pubitemid 39386566)
20. Davidson E. P., Kleinschmidt T. L., Oltman C. L., Lund D. D., Yorek M. A., Treatment of streptozotocin-induced diabetic rats with AVE7688, a vasopeptidase inhibitor: effect on vascular and neural disease Diabetes 2007 56 2 355 362
21. Oltman C. L., Davidson E. P., Coppey L. J., Kleinschmidt T. L., Dake B., Yorek M. A., Role of the effect of inhibition of neutral endopeptidase on vascular and neural complications in streptozotocin-induced diabetic rats European Journal of Pharmacology 2011 650 2-3 556 562
22. Davidson E. P., Coppey L. J., Kleinschmidt T. L., Oltman C. L., Yorek M. A., Vascular and neural dysfunctions in obese Zucker rats: effect of AVE7688 Experimental Diabetes Research 2009 2009 912327
23. Yorek M. A., The potential role of angiotensin converting enzyme and vasopeptidase inhibitors in the treatment of diabetic neuropathy Current Drug Targets 2008 9 1 77 84 (Pubitemid 351201682)
24. Doupis J., Veves A., DPP4 inhibitors: a new approach in diabetes treatment. Advances in Therapy 2008 25 7 627 643
25. Ahrén B., Emerging dipeptidyl peptidase-4 inhibitors for the treatment of diabetes Expert Opinion on Emerging Drugs 2008 13 4 593 607
26. Lambeir A. M., Scharpé S., De Meester I., DPP4 inhibitors for diabetes-What next? Biochemical Pharmacology 2008 76 12 1637 1643
27. Verspohl E. J., Novel therapeutics for type 2 diabetes: incretin hormone mimetics (glucagon-like peptide-1 receptor agonists) and dipeptidyl peptidase-4 inhibitors Pharmacology and Therapeutics 2009 124 1 113 138
28. Moritoh Y., Takeuchi K., Asakawa T., Kataoka O., Odaka H., Chronic administration of alogliptin, a novel, potent, and highly selective dipeptidyl peptidase-4 inhibitor, improves glycemic control and beta-cell function in obese diabetic ob/ob mice European Journal of Pharmacology 2008 588 2-3 325 332
29. Moritoh Y., Takeuchi K., Hazama M., Chronic administration of voglibose, an -glucosidase inhibitor, increases active glucagon-like peptide-1 levels by increasing its secretion and decreasing dipeptidyl peptidase-4 activity in ob/ob mice Journal of Pharmacology and Experimental Therapeutics 2009 329 2 669 676
30. Tahara A., Matsuyama-Yokono A., Nakano R., Someya Y., Hayakawa M., Shibasaki M., Antihyperglycemic effects of ASP8497 in streptozotocin- nicotinamide induced diabetic rats: comparison with other dipeptidyl peptidase-IV inhibitors Pharmacological Reports 2009 61 5 899 908
31. Matsuyama-Yokono A., Tahara A., Nakano R., Someya Y., Hayakawa M., Shibasaki M., Chronic inhibition of dipeptidyl peptidase-IV with ASP8497 improved the HbA1c level, glucose intolerance, and lipid parameter level in streptozotocin-nicotinamide-induced diabetic mice Naunyn-Schmiedeberg's Archives of Pharmacology 2009 379 2 191 199
32. Wiese T. J., Lowe W. L. Jr., Yorek M. A., Regulation of the Na+/myo-inositol cotransporter mRNA levels in streptozotocin-induced diabetic rats and by hyperglycemia in cultured cells International Journal of Diabetes 1996 4 107 121
33. Davidson E., Coppey L., Lu B., Arballo V., Calcutt N. A., Gerard C., Yorek M., The roles of streptozotocin neurotoxicity and neutral endopeptidase in murine experimental diabetic neuropathy Experimental Diabetes Research 2009 2009 431980
34. Sugimoto K., Kojima K., Baba M., Yasujima M., Olmesartan ameliorates peripheral nerve dysfunction in Zucker diabetic fatty rats Journal of Hypertension 2011 29 7 1337 1346
35. Obrosova I. G., Xu W., Lyzogubov V. V., Ilnytska O., Mashtalir N., Vareniuk I., Pavlov I. A., Zhang J., Slusher B., Drel V. R., PARP inhibition or gene deficiency counteracts intraepidermal nerve fiber loss and neuropathic pain in advanced diabetic neuropathy Free Radical Biology and Medicine 2008 44 6 972 981 (Pubitemid 351318144)
36. Drel V. R., Pacher P., Vareniuk I., Pavlov I., Ilnytska O., Lyzogubov V. V., Tibrewala J., Groves J. T., Obrosova I. G., A peroxynitrite decomposition catalyst counteracts sensory neuropathy in streptozotocin-diabetic mice European Journal of Pharmacology 2007 569 1-2 48 58 (Pubitemid 47175883)
37. Stavniichuk R., Drel V. R., Shevalye H., Maksimchyk Y., Kuchmerovska T. M., Nadler J. L., Obrosova I. G., Baicalein alleviates diabetic peripheral neuropathy through inhibition of oxidative-nitrosative stress and p38 MAPK activation Experimental Neurology 2011 230 1 106 113
38. Beiswenger K. K., Calcutt N. A., Mizisin A. P., Dissociation of thermal hypoalgesia and epidermal denervation in streptozotocin-diabetic mice Neuroscience Letters 2008 442 3 267 272
39. Jin H. Y., Liu W. J., Park J. H., Baek H. S., Park T. S., Effect of Dipeptidyl Peptidase-IV (DPP-IV) Inhibitor (Vildagliptin) on Peripheral Nerves in Streptozotocin-induced Diabetic Rats Archives of Medical Research 2009 40 7 536 544
40. Nauck M. A., El-Ouaghlidi A., The therapeutic actions of DPP-IV inhibition are not mediated by glucagon-like peptide-1 Diabetologia 2005 48 4 608 611 (Pubitemid 40591212)